此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 Imetelstat 在 HMA 治疗失败的高危 MDS 或 AML 患者中的研究 (IMpress)

2026年9月10日 更新者:GCP-Service International West GmbH

一项评估 Imetelstat 在 HR 骨髓增生异常综合征或基于 HMA 治疗失败的 AML 患者中的疗效和安全性的 II 期研究

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

研究概览

研究类型

介入性

注册 (实际的)

46

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Düsseldorf、德国
        • Marien Hospital Düsseldorf
      • Jena、德国
        • Universität Jena, Medizinische Fakultät
      • Leipzig、德国
        • Universität Leipzig, Medizinische Fakultät
      • München、德国
        • Klinikum rechts der Isar
      • Nantes、法国
        • CHU Nantes - Hôtel Dieu
      • Nice、法国
        • Hôpital Archet 1
      • Paris、法国
        • Hôpital Saint-Louis
      • Toulouse、法国
        • CHU de Toulouse
      • Adelaide、澳大利亚
        • Royal Adelaide Hospital
      • Brisbane、澳大利亚
        • Royal Brisbane and Women's Hospitals
      • Nedlands、澳大利亚
        • Linear Clinical Research

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Signed written informed consent
  • Male and female ≥ 18 years at the first screening
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Initial diagnosis of AML or MDS according to WHO (World Health Organization) 2016 classification
  • At least one cytopenia
  • Failure to achieve complete or partial response or hematological improvement observed after at least six azacitidine monotherapy or four decitabine monotherapy based 4-week treatment cycles administered during the past two years OR Failure to achieve complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least six (azacitidine) or four (decitabine) based 4-week treatment cycles administered during the past two years OR Relapse after initial complete or partial response or hematological improvement observed after at least two 4-week treatment cycles with azacitidine plus venetoclax or with decitabine plus venetoclax during the past two years OR Intolerance to treatment with HMA-based therapy during the past two years
  • Not eligible for allogeneic stem cell transplantation
  • ≥ 5% bone marrow blasts at screening
  • Off all other treatments for AML/MDS for at least 14 days; granulocyte colony-stimulating factor (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Biochemical laboratory test values must be within the defined limits.
  • Availability of blood counts and transfusion events for previous 16 weeks
  • Women of childbearing potential and practicing a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies. For females, these restrictions apply for 3 months after the end of dosing.
  • A woman of childbearing potential must have a negative serum or urine pregnancy test at screening and agree to be tested on day 1 of every cycle and at End of Treatment (EOT)
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control. For males, these restrictions apply for 3 months after the end of dosing
  • Patients who are relapsed or refractory to, or not eligible for, therapy with approved and available FLT3 (FMS-like tyrosine kinase 3) or IDH1/IDH2 (Isocitrate dehydrogenase) inhibitors or other approved targeted therapies.

Exclusion Criteria:

  • Chemotherapy within the 14 days prior to the first dose of imetelstat being administered (other than hydroxyurea)
  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients (refer to the Investigators Brochure (IB))
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days prior to day 1 of Cycle 1
  • Prior treatment with imetelstat
  • Prior history of intensive chemotherapy or hematopoietic stem cell transplant
  • Major surgery within 4 weeks prior to day 1 of Cycle 1 (excluding the placement of vascular access and other minor surgical procedures)
  • Diagnosed or treated for malignancy other than MDS or AML, except:

Malignancy treated with curative intent and with no known active disease present for 3 years before day 1 of Cycle 1 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease

  • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of day 1 of Cycle 1, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
  • Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics
  • Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), or known acute or chronic liver disease including cirrhosis
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the participant 's safety, interfere with the imetelstat metabolism, or put the study outcomes at undue risk; Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Females who are pregnant or are currently breastfeeding or planning to become pregnant while enrolled in this study or within 3 months after the end of dosing
  • Participant is a man who plans to father a child while enrolled in this study or within 3 months after the end of dosing
  • Other:

Participant is in custody by order of an authority or a court of law Participation in another interventional clinical study within the last 3 months prior to signing the Informed consent form (ICF) or simultaneous participation in other interventional clinical studies Previous assignment to treatment during this study Close affiliation with the investigator (e.g., a close relative) or persons working at the study site Participant is an employee of the sponsor or involved Contract Research Organization (CRO) Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the Participant's safety

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:单臂imetelstat

Intravenous injection

其他名称:
  • GRN163L

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Hematological Response Rate of Participants After Treatment With Imetelstat
大体时间:Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

The combined response assessment criteria for MDS and AML based on IWG (International Working Group) 2018 criteria (MDS) and the criteria of the European LeukemiaNet (AML) will be used to define responders.

The response rate is calculated as number of responders divided by the number of all participants of the analysis set.

Up to Week 17 (Visit 9; approximately 17 weeks after first dose).

次要结果测量

结果测量
措施说明
大体时间
Toxicity Measured by NCI CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events Version 5.0)
大体时间:From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. A treatment-emergent adverse event (TEAE) was defined as any adverse event arising or worsening after the first dose of study drug. The number of participants experiencing at least one TEAE was summarized in the Safety Evaluation Set.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

其他结果措施

结果测量
措施说明
大体时间
Treatment Duration (Days)
大体时间:From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.

The number of days between the first and last doses of study treatment. Subjects who discontinued early have duration calculated to their final dose date.

From Treatment Start (Cycle 1 Day 1) to End of Treatment (EOT). Duration varies by subject.
Treatment Compliance
大体时间:From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).

Percentage of study-drug doses received relative to the number of doses planned per protocol.

Computed as: Compliance (%) = (Actual doses received ÷ Planned doses) × 100. Missed or undocumented doses are counted as not received unless justified per protocol or Statistical Analysis Plan (SAP). Dose holds and reductions are included in compliance assessment.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject).
Cumulative Dose (mg)
大体时间:From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

Total amount of imetelstat (mg) received across all treatment administrations. Calculated as the sum of all administered doses documented in the dose-administration eCRF (electronic Case Report Form).

Notes: Dose reductions, missed doses, and dose delays are captured in the calculation. Missing dose records default to "not administered" unless clarified.

From first dose of imetelstat through the last dose received, including follow-up to 28 ± 5 days after the last dose (duration varies by subject)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月5日

初级完成 (实际的)

2025年3月27日

研究完成 (实际的)

2025年9月30日

研究注册日期

首次提交

2022年10月13日

首先提交符合 QC 标准的

2022年10月13日

首次发布 (实际的)

2022年10月17日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月10日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅